-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Monte Rosa Therapeutics (NASDAQ:GLUE) and Kodiak Sciences (NASDAQ:KOD) Financial Comparison
Monte Rosa Therapeutics (NASDAQ:GLUE) and Kodiak Sciences (NASDAQ:KOD) Financial Comparison
Kodiak Sciences (NASDAQ:KOD – Get Rating) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.
Risk & Volatility
Kodiak Sciences has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.
Get Kodiak Sciences alerts:Earnings & Valuation
This table compares Kodiak Sciences and Monte Rosa Therapeutics' gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Kodiak Sciences | N/A | N/A | -$266.99 million | ($6.83) | -1.15 |
Monte Rosa Therapeutics | N/A | N/A | -$73.96 million | N/A | N/A |
Insider & Institutional Ownership
80.0% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 83.2% of Monte Rosa Therapeutics shares are owned by institutional investors. 42.6% of Kodiak Sciences shares are owned by company insiders. Comparatively, 3.5% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Kodiak Sciences and Monte Rosa Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Kodiak Sciences | N/A | -62.79% | -43.74% |
Monte Rosa Therapeutics | N/A | -31.95% | -28.20% |
Analyst Recommendations
This is a summary of recent ratings and price targets for Kodiak Sciences and Monte Rosa Therapeutics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Kodiak Sciences | 2 | 3 | 3 | 0 | 2.13 |
Monte Rosa Therapeutics | 0 | 1 | 3 | 0 | 2.75 |
Kodiak Sciences currently has a consensus price target of $25.11, indicating a potential upside of 218.67%. Monte Rosa Therapeutics has a consensus price target of $18.60, indicating a potential upside of 149.66%. Given Kodiak Sciences' higher probable upside, research analysts clearly believe Kodiak Sciences is more favorable than Monte Rosa Therapeutics.
Summary
Monte Rosa Therapeutics beats Kodiak Sciences on 5 of the 8 factors compared between the two stocks.
About Kodiak Sciences
(Get Rating)
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
About Monte Rosa Therapeutics
(Get Rating)
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
Kodiak Sciences (NASDAQ:KOD – Get Rating) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.
科迪亚克科学公司(纳斯达克:KOD-GET评级)和蒙特罗莎治疗公司(纳斯达克:GLUE-GET评级)都是小盘医疗公司,但哪一家是优势业务?我们将根据分析师的建议、盈利能力、机构持股、估值、股息、风险和收益对这两家公司进行比较。
Risk & Volatility
风险与波动性
Kodiak Sciences has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.
Kodiak Sciences的贝塔系数为1.76,表明其股价的波动性比标准普尔500指数高76%。相比之下,蒙特罗萨治疗公司的贝塔系数为0.97,表明其股价的波动性比标准普尔500指数低3%。
Earnings & Valuation
收益与估值
This table compares Kodiak Sciences and Monte Rosa Therapeutics' gross revenue, earnings per share and valuation.
此表比较了科迪亚克科学公司和蒙特罗萨治疗公司的毛收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Kodiak Sciences | N/A | N/A | -$266.99 million | ($6.83) | -1.15 |
Monte Rosa Therapeutics | N/A | N/A | -$73.96 million | N/A | N/A |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
科迪亚克科学 | 不适用 | 不适用 | -2.6699亿美元 | ($6.83) | -1.15 |
蒙特罗萨治疗公司 | 不适用 | 不适用 | -7,396万元 | 不适用 | 不适用 |
Insider & Institutional Ownership
内部人与机构所有权
80.0% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 83.2% of Monte Rosa Therapeutics shares are owned by institutional investors. 42.6% of Kodiak Sciences shares are owned by company insiders. Comparatively, 3.5% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
科迪亚克科学公司80.0%的股份由机构投资者持有。相比之下,蒙特罗萨治疗公司83.2%的股份由机构投资者持有。科迪亚克科学公司42.6%的股份由公司内部人士持有。相比之下,蒙特罗萨治疗公司3.5%的股份由公司内部人士持有。强大的机构持股表明,大型基金管理公司、对冲基金和捐赠基金相信,一只股票的长期表现将好于大盘。
Profitability
盈利能力
This table compares Kodiak Sciences and Monte Rosa Therapeutics' net margins, return on equity and return on assets.
下表比较了科迪亚克科学公司和蒙特罗萨治疗公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Kodiak Sciences | N/A | -62.79% | -43.74% |
Monte Rosa Therapeutics | N/A | -31.95% | -28.20% |
净利润率 | 股本回报率 | 资产回报率 | |
科迪亚克科学 | 不适用 | -62.79% | -43.74% |
蒙特罗萨治疗公司 | 不适用 | -31.95% | -28.20% |
Analyst Recommendations
分析师建议
This is a summary of recent ratings and price targets for Kodiak Sciences and Monte Rosa Therapeutics, as provided by MarketBeat.
这是由MarketBeat提供的科迪亚克科学公司和蒙特罗萨治疗公司最近的评级和目标价摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Kodiak Sciences | 2 | 3 | 3 | 0 | 2.13 |
Monte Rosa Therapeutics | 0 | 1 | 3 | 0 | 2.75 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
科迪亚克科学 | 2 | 3 | 3 | 0 | 2.13 |
蒙特罗萨治疗公司 | 0 | 1 | 3 | 0 | 2.75 |
Kodiak Sciences currently has a consensus price target of $25.11, indicating a potential upside of 218.67%. Monte Rosa Therapeutics has a consensus price target of $18.60, indicating a potential upside of 149.66%. Given Kodiak Sciences' higher probable upside, research analysts clearly believe Kodiak Sciences is more favorable than Monte Rosa Therapeutics.
科迪亚克科学公司目前的一致目标价为25.11美元,表明潜在上行空间为218.67%。蒙特罗萨治疗公司的共识目标价为18.6美元,这表明潜在的上涨幅度为149.66。鉴于科迪亚克科学公司更有可能上行,研究分析师显然认为科迪亚克科学公司比蒙特罗萨治疗公司更有利。
Summary
摘要
Monte Rosa Therapeutics beats Kodiak Sciences on 5 of the 8 factors compared between the two stocks.
与两只股票相比,蒙特罗萨治疗公司在8个因素中有5个击败了科迪亚克科学公司。
About Kodiak Sciences
科迪亚克科学公司简介
(Get Rating)
(获取评级)
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
科迪亚克科学公司是一家临床阶段的生物制药公司,研究、开发和商业化治疗视网膜疾病的疗法。它的主要候选产品是KSI-301,这是一种处于IIb/III期临床研究的抗血管内皮生长因子抗体生物聚合物,用于治疗湿性老年性黄斑变性,以及治疗糖尿病黄斑水肿、视网膜静脉阻塞引起的naïve黄斑水肿和非增殖性糖尿病视网膜病变。该公司的临床前候选产品包括KSI-501,一种治疗含有炎症成分的视网膜疾病的双特异性结合物;以及KSI-601,一种治疗干性AMD的三联抑制剂。该公司前身为奥利加西有限责任公司,并于2015年9月更名为科迪亚克科学公司。科迪亚克科学公司成立于2009年,总部设在加利福尼亚州帕洛阿尔托。
About Monte Rosa Therapeutics
关于蒙特罗萨治疗公司
(Get Rating)
(获取评级)
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
蒙特罗萨治疗公司是一家生物制药公司,致力于开发新型小分子精密药物,这种药物利用人体的自然机制选择性地降解与治疗相关的蛋白质。它为GSPT1开发了一种口服分子胶降解剂,GSPT1是一种翻译终止因子和含有降解的蛋白质,用于治疗Myc驱动的癌症。该公司还开发了用于治疗卵巢癌、子宫癌和乳腺癌的CDK2;用于治疗炎症性疾病(如克罗恩病、神经退行性疾病、糖尿病和肝病)的NEK7;用于自身免疫疾病的靶蛋白Vav1;以及用于治疗血红蛋白疾病的BCL11A。蒙特罗萨治疗公司成立于2019年,总部设在马萨诸塞州波士顿。
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《科迪亚克科学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Kodiak Sciences和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧